TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Drug May Impede Thyroid Cancer A study of an experimental AstraZeneca drug, vandetanib, showed it delayed the progression of a rare type of thyroid cancer. online.wsj.com |
Big Pharma Won't Wait in Rush for Biotech's Drugs Rising pressure to find new products is prompting big pharmaceutical companies to license or acquire biotechnology companies' experimental medicines when they've barely been tested in human trials. online.wsj.com |
Court Decision Puts Pressure on Embryonic Stem Cell Stocks Wall Street Cheat Sheet submits: By Elliot Turner Shares of research stage embryonic stem cell companies Geron (NASDAQ: GERN) and StemCells, Inc. (NASDAQ: STEM) were trading lower Tuesday after a federal judge issued a preliminary injunction against all government funding of embryonic stem cell research (ESC). Shares of Osiris Therapeutics (OSIR), on the other hand, were trading higher, as the company’s research is exclusively dealing with adult stem cells (ASC), which is acceptable under this ruling.Complete Story » seekingalpha.com |
Analyzing Major Big Pharma Players Using Relative Valuation According to IMS Health, the global market for pharmaceuticals is expected to grow at an annual rate of 5 to 8 percent and reach $1.1 trillion by the year 2014. Unfortunately, outside of some mutual funds, I do not have any exposure to this sector in my personal account. In addition to scope for capital appreciation (based on sector growth), many of the big pharma firms also offer an attractive dividend. In the next few articles, I will attempt to determine the valuation and investment potential for the pharma companies currently present in my watch list and hopefully add the most attractive companies to my portfolio. This article presents the relative analysis results conducted for 6 major drug companies namely Abbott Laboratories (ABT), Merck & Co. (MRK), Bristol Myers Squibb (BMY), Eli Lilly & Co. (LLY), GlaxoSmithKline (GSK), and Novartis (NVS). Complete Story » seekingalpha.com |
Latest Developments in the Pharmathene-SIGA Case Point to a Strong Buy for PIP James Altucher submits:There’s been significant developments in the PIP-SIGA case since my last article (written when PIP was at $1.90) and I wanted to both summarize them and also establish some facts that seem to be points of confusion on the various message boards out there: Fact: SIGA has tried twice now to dismiss the case or portions of the case (note that this most recent attempt was an attempt at a partial dismissal) and twice the judge has ruled that this is going to trial. The second dismissal was predicted in my first article.Complete Story » seekingalpha.com |